Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease.

@article{Yamada2010ComparisonOI,
  title={Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease.},
  author={Yukiko Yamada and Sunao Sugita and Hiroyuki Tanaka and Koju Kamoi and Tatsushi Kawaguchi and Manabu Mochizuki},
  journal={The British journal of ophthalmology},
  year={2010},
  volume={94 3},
  pages={284-8}
}
AIM To compare the efficacy and safety of infliximab versus ciclosporin A (CsA) in refractory uveoretinitis in Behçet disease. METHODS In this retrospective clinical chart review of patients with Behçet disease who were treated with CsA or infliximab, we collected information on the number of uveitis attacks, visual acuity and adverse side effects that occurred during the 6 months prior to and after the initiation of CsA (n=20) or infliximab (n=17). RESULTS The number of acute episodes of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 48 extracted citations

The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review.

Clinical reviews in allergy & immunology • 2017
View 6 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 16 references

Similar Papers

Loading similar papers…